CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← TAKEDA PHARMACEUTICAL CO LTD (TAK) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

TAKEDA PHARMACEUTICAL CO LTD (TAK)

Pharmaceutical Preparations · market cap $60.2B · as of 2026-10-16

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-11-30 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Takeda (TAK) is a large, diversified Japanese pharmaceutical company with roughly 49,578 employees. Its stated focus areas are oncology, rare diseases, neuroscience, gastroenterology and plasma-derived therapies. At ~$19.45 across ~1.56B shares, the market cap is about $30.3B. Our calendar shows a dense run of estimated readouts over the next four months: Phase 3 events for TAK-788, TAK-360, Maribavir and Teduglutide, Phase 2 events for TAK-788, TAK-360, Ixazomib, FOLFIRI and TAK-279, plus earnings on 2026-10-29.
The catalyst path
  • 2026-11-30 (est.)Phase 2 · TAK-360imp 7/10
  • 2026-12-15 (est.)Phase 2 · Ixazomibimp 7/10
  • 2027-01-15 (est.)Phase 2 · FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)imp 7/10
  • 2027-01-18 (est.)Phase 3 · Maribavirimp 9/10
  • 2027-02-05 (est.)Phase 2 · Zasocitinib (Dose A)imp 7/10
  • 2027-02-10 (est.)Phase 3 · Teduglutideimp 9/10
  • 2027-02-17 (est.)Phase 2 · TAK-279imp 7/10
  • 2027-03-15 (est.)Phase 2 · C1 Esterase Inhibitor Injectionimp 7/10
Pipeline
AssetPhaseIndication
REPLAGALPhase 3Fabry Disease
IGSCPhase 3Primary Immunodeficiency Disease
Alogliptin and pioglitazonePhase 3Type 2 Diabetes Mellitus
B-MAD chemotherapyPhase 2Extranodal NK/T-cell Lymphoma
HYQVIAPhase 3Primary Immunodeficiency Diseases (PID)
Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)Phase 2Dengue Fever
Leuprorelin acetatePhase 2Endometriosis
Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medicationsPhase 3Hypertension
FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)Phase 2Colon Cancer
Lapaquistat acetate and atorvastatinPhase 3Hypercholesterolemia
GlyburidePhase 3Diabetes Mellitus
Lapaquistat acetate and additional lipid-lowering therapyPhase 3Hypercholesterolemia
Azilsartan medoxomil with or without add-on hydrochlorothiazidePhase 3Hypertension
HCTZPhase 3Essential Hypertension
TAK-536CCB tabletPhase 3Essential Hypertension
ColchicinePhase 3Atrial Fibrillation
VedolizumabPhase 3Colitis, Ulcerative
TAK-861Phase 3Narcolepsy Type 1
Azilsartan medoxomil and chlorthalidonePhase 3Essential Hypertension
Zasocitinib (Dose A)Phase 2Hidradenitis Suppurativa
Price & technical context
3-month
+20.4%
6-month
+31.1%
12-month
+52.6%
52-wk range
$14.06–$21.73
vs 50-day MA
+11.7%
vs 200-day MA
+22.1%
Realized vol
21.3%
Max drawdown
-20.1%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for TAK (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.